From the publishers of JADPRO

Acute Lymphoblastic Leukemia Resource Center

Advertisement

Changes in symptom clusters over the course of chemotherapy in children with acute lymphoblastic leukemia: A longitudinal survey

Last Updated: Thursday, March 27, 2025

This study evaluated symptom progression in 102 children with acute lymphoblastic leukemia (ALL). Using the Memorial Symptom Assessment Scale for Children (MSAS-C), researchers found an average of 15.52 symptoms per child. Symptom clusters changed across chemotherapy phases, expanding from emotional, gastrointestinal, and somatic initially to include neurological, self-image disturbance, and skin/mucosal symptoms later. The study concluded that dynamic symptom clusters necessitate tailored interventions.

Journal Of Pediatric Health Care
Advertisement
News & Literature Highlights

Discover Oncology

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: A case series and literature review

Frontiers in Oncology

Impact of standardized immunophenotyping and MRD monitoring on early mortality reduction in childhood leukemia: A step towards addressing healthcare disparities in vulnerable populations from Southern Mexico

Clinical and Experimental Pediatrics

Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/ refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis

Medical Journal, Armed Forces India

Bone mineral density in childhood acute lymphoblastic leukaemia survivors and factors affecting it

Blood Advances

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Pediatrics International: Official Journal of the Japan Pediatric Society

Safety and efficacy of sedation for pediatric patients with cancer and developmental disabilities

BMC Ophthalmology

Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution

Leukemia

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial

Cancer

Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Clinical Laboratory

T-acute lymphoblastic leukemia/lymphoma manifesting as acute renal failure

Advertisement
Advertisement